Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
Acumen Health Holdings has announced that its subsidiary, PRN Physician Recommended Nutriceuticals, will acquire the Avenova® brand from NovaBay Pharmaceuticals (NYSE American: NBY). The acquisition, expected to close in Q4 2024, will enhance PRN's portfolio of science-based eye health products. Avenova® offers products for ocular health, including cleansing sprays, wipes, and heated eye masks, with its leading product being a hypochlorous acid spray for eye hygiene.
PRN plans to leverage its existing sales force and relationships with eye care professionals to expand access and awareness of Avenova® products. This marks PRN's sixth add-on acquisition in five years, aligning with its strategy to grow in the eye health market both organically and through acquisitions.
Acumen Health Holdings ha annunciato che la sua filiale, PRN Physician Recommended Nutriceuticals, acquisterà il marchio Avenova® da NovaBay Pharmaceuticals (NYSE American: NBY). L'acquisizione, prevista per chiudere nel Q4 2024, migliorerà il portafoglio di PRN di prodotti per la salute degli occhi basati sulla scienza. Avenova® offre prodotti per la salute oculare, inclusi spray detergenti, salviette e maschere riscaldate per gli occhi, con il suo prodotto di punta rappresentato da uno spray a base di acido ipocloroso per l'igiene degli occhi.
PRN prevede di utilizzare la propria forza vendita esistente e le relazioni con i professionisti della cura degli occhi per espandere l'accesso e la consapevolezza dei prodotti Avenova®. Questo segna la sesta acquisizione aggiuntiva di PRN in cinque anni, in linea con la sua strategia di crescita nel mercato della salute oculare sia organicamente che attraverso acquisizioni.
Acumen Health Holdings ha anunciado que su filial, PRN Physician Recommended Nutriceuticals, adquirirá la marca Avenova® de NovaBay Pharmaceuticals (NYSE American: NBY). Se espera que la adquisición se cierre en el cuarto trimestre de 2024, lo que mejorará el portafolio de PRN de productos para la salud ocular basados en la ciencia. Avenova® ofrece productos para la salud ocular, incluidos sprays limpiadores, toallitas y máscaras térmicas para los ojos, siendo su producto líder un spray de ácido hipocloroso para la higiene ocular.
PRN planea aprovechar su fuerza de ventas existente y las relaciones con los profesionales de cuidado ocular para ampliar el acceso y la concienciación sobre los productos de Avenova®. Esta es la sexta adquisición adicional de PRN en cinco años, alineándose con su estrategia de crecimiento en el mercado de la salud ocular tanto de manera orgánica como a través de adquisiciones.
Acumen Health Holdings는 그 자회사인 PRN Physician Recommended Nutriceuticals가 NovaBay Pharmaceuticals (NYSE American: NBY)로부터 Avenova® 브랜드를 인수할 것이라고 발표했습니다. 2024년 4분기에 완료될 것으로 예상되는 이번 인수는 PRN의 과학 기반 안과 건강 제품 포트폴리오를 강화할 것입니다. Avenova®는 안구 건강을 위한 청소 스프레이, 티슈, 그리고 온열 눈 마스크를 포함한 제품을 제공하며, 주요 제품은 안구 위생을 위한 저염소산 스프레이입니다.
PRN은 기존의 판매 인력 및 안과 전문가들과의 관계를 활용하여 Avenova® 제품의 접근성과 인식을 확대할 계획입니다. 이는 PRN의 5년간 6번째 추가 인수입니다, 이는 유기적 성장은 물론 인수를 통해 안과 건강 시장에서 성장하겠다는 전략에 부합합니다.
Acumen Health Holdings a annoncé que sa filiale, PRN Physician Recommended Nutriceuticals, acquerra la marque Avenova® de NovaBay Pharmaceuticals (NYSE American: NBY). L'acquisition, qui devrait être finalisée au quatrième trimestre 2024, renforcera le portefeuille de PRN de produits pour la santé des yeux basés sur la science. Avenova® propose des produits pour la santé oculaire, notamment des sprays nettoyants, des lingettes et des masques pour les yeux chauffés, son produit phare étant un spray d'acide hypochloreux pour l'hygiène des yeux.
PRN prévoit de tirer parti de sa force de vente existante et de ses relations avec les professionnels des soins oculaires pour élargir l'accès et la sensibilisation aux produits Avenova®. Cela marque la sixième acquisition supplémentaire de PRN en cinq ans, s'inscrivant dans sa stratégie de croissance sur le marché de la santé des yeux à la fois de manière organique et par le biais d'acquisitions.
Acumen Health Holdings hat angekündigt, dass ihre Tochtergesellschaft PRN Physician Recommended Nutriceuticals die Marke Avenova® von NovaBay Pharmaceuticals (NYSE American: NBY) übernehmen wird. Der Abschluss der Übernahme wird im 4. Quartal 2024 erwartet und wird das Portfolio von PRN an wissenschaftlich fundierten Augenpflegeprodukten erweitern. Avenova® bietet Produkte für die Augengesundheit an, darunter Reinigungssprays, Tücher und beheizte Augenmasken, wobei das führende Produkt ein hypochloriges Sprays zur Augenhygiene ist.
PRN plant, seine bestehende Verkaufsstruktur und die Beziehungen zu Augenpflege-Profis zu nutzen, um den Zugang und das Bewusstsein für Avenova® Produkte zu erweitern. Dies ist die sechste Zusatzübernahme von PRN in fünf Jahren, was mit seiner Strategie übereinstimmt, im Bereich Augengesundheit sowohl organisch als auch durch Übernahmen zu wachsen.
- Acquisition expands PRN's product portfolio in the eye health market
- Potential for increased market reach through PRN's existing sales channels
- Strengthens PRN's position in the science-based eye health products sector
- Aligns with PRN's growth strategy through acquisitions
- None.
The acquisition of Avenova by Acumen Health Holdings is a strategic move that could potentially boost PRN's market position in the eye health sector. This deal aligns with PRN's growth strategy, marking their sixth acquisition in five years. While financial details are not disclosed, the transaction likely offers synergistic benefits for PRN.
Investors should note that this acquisition diversifies PRN's product portfolio, potentially leading to increased revenue streams. The company's plan to leverage its existing sales force and professional relationships could result in cost-efficient expansion of Avenova's market reach. However, the impact on Acumen's financials and the deal's ROI remain uncertain without specific financial figures.
This acquisition signals growing consolidation in the eye health market, reflecting the industry's potential. Avenova's pioneering use of hypochlorous acid in eyecare products suggests a trend towards innovative, science-based solutions in this sector. PRN's focus on expanding through both organic growth and acquisitions indicates a robust market demand for eye health products.
The multi-channel distribution strategy of Avenova (direct-to-consumer, professional and retail pharmacy) aligns well with current market trends, potentially allowing PRN to capture a wider consumer base. However, investors should monitor how effectively PRN integrates and expands Avenova's market presence, as this will be important for realizing the acquisition's full value.
The acquisition of Avenova strengthens PRN's position in the science-based eye health products market. Hypochlorous acid, the active ingredient in Avenova's leading product, has shown promise in promoting eye hygiene. This aligns with the growing emphasis on preventive eye care and could meet increasing consumer demand for non-pharmaceutical eye health solutions.
However, the long-term success of this acquisition will depend on ongoing research and development to maintain the product's efficacy and relevance. Investors should watch for any future clinical studies or product improvements that could further validate Avenova's effectiveness and drive market growth. The integration of Avenova into PRN's portfolio may also spur new product innovations, potentially creating additional value.
This Acquisition Enhances PRN Physician Recommended Nutriceuticals' ("PRN") Product Portfolio of Science-Based Eye Health Products
The acquisition of the Brand will bolster PRN's existing portfolio and strengthen PRN's commitment to deliver high-quality products that have a meaningful impact on patients' eye health. PRN will leverage their existing sales force and relationships with optometrists and ophthalmologists to expand access and awareness of Avenova® products.
"The Brand pioneered the use of hypochlorous acid in eyecare and has a long history of success in the professional channel," said Scott Woodruff, CEO of Acumen Health Holdings. "This exciting acquisition broadens PRN's existing eye health product portfolio and allows PRN to better serve patients through offering an expanded suite of science-based eye health products."
The deal builds on PRN's strategy to grow its presence in the eye health market organically and through acquisitions. Avenova® will represent the sixth add-on acquisition completed by PRN in the past 5 years.
Please see the NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) press release for information regarding their go-forward plans following this transaction.
Alex Putala
(920) 255-4972
960 Harvest Drive, Suite B250
View original content to download multimedia:https://www.prnewswire.com/news-releases/acumen-health-holdings-acumen-to-acquire-the-avenova-brand-from-novabay-pharmaceuticals-302253803.html
SOURCE Acumen Health Holdings
FAQ
What is Acumen Health Holdings acquiring from NovaBay Pharmaceuticals (NBY)?
When is the acquisition of Avenova® by PRN expected to close?
What products does the Avenova® brand offer?
How many acquisitions has PRN completed in the past 5 years, including Avenova®?
